Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer
DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified
using genome-wide expression profile analysis by the use of cDNA microarray in our previous
studies. We have determined the HLA-A*2402 restricted epitope peptides derived from DEPDC1,
DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production
when stimulated with the appropriate targets expressed the appropriate protein and
HLA-A*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined
after the vaccination. Therefore we focused on the safety and efficacy of novel vaccination
for the advanced bladder cancer patients who already showed resistance to standard
chemotherapies or radiotherapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
feasibility (toxicities as assessed by NCI-CTCAE version 3)
Tomoaki Fujioka, M.D. & Ph.D.
Department of Urology, Iwate Medical University
Japan: Ministry of Health, Labor and Welfare